McClellan Urges Rigor In Pharmacogenomic R&D: Less Art, More Science
This article was originally published in The Gray Sheet
Executive Summary
Linking microarray results to clinical outcomes will provide a more stable scientific platform for product development, FDA Commissioner Mark McClellan emphasized during an inaugural speech at the National Cancer Institute Director's Seminar Series
You may also be interested in...
Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance
NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions
Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance
NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions
Genetic Test Reimbursement Issues Get Top Billing On SACGHS Priority List
Concerns that inadequate genetic test reimbursement could hinder lab adoption of the technology have spurred the HHS Secretary's Advisory Committee on Genetics, Health & Society to rank the issue first on its list of priorities for in-depth analysis